Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. Gerogianni (Larissa, Greece), R. Jagirdar (Larissa, Greece), E. Pitaraki (Larissa, Greece), O. Kouliou (Larissa, Greece), C. Hatzoglou (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), S. Zaroginannis (Larissa, Greece). Effects of 2-Deoxy-glucose (2DG) with cisplatin and pemetrexed in mesothelioma cell mediated collagen gel contraction.. 3800

Member's Comments

No comment yet.

Related content which might interest you: 2-Deoxy-glucose synergizes with Cisplatin and Pemetrexed chemotherapeutics to reduce cell migration of mesothelioma cells Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019 A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Effects of Cisplatin and Pemetrexed on the cell viability and cell adhesion of benign mesothelial and mesothelioma cells. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Interplaying between Gamma-H2AX and autophagy in A549 cells treated with cisplatin and etoposide Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 A phase III randomised study comparing concomitant standard cisplatin (P) – etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Comparison of vinorelbine containing dublet versus triplet schedule (vinorelbine cisplatin versus vinorelbine-ifosfamide cisplatin) in NSCLC Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α Source: Eur Respir J 2008; 32: 443-451 Year: 2008 Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 New induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) followed by concomitant (Con) chemoradiotherapy in stage IIIB non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001 Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002 Generating senescent airway epithelial cell populations using low-concentration doxorubicin or etoposide Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021